Pharma
CONEXEN - Informal Networking in Cambridge - 28 Feb 2024
CONEXEN is a networking group for professionals working in the life sciences, biopharma, medical devices and health tech industries. Join us on February 28th Pre-registration is still open. ...
Supporting a Phase III R&D strategy within the anti-infective space
Client Issue An emerging pharmaceutical company sought to evaluate Phase III development strategies for an anti-infective drug with potential to treat a range of patient populations. ...
Establishing real-world testing and treatment patterns for EGFR NSCLC patients
Client issue Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China (mainland, HK, and Taiwan). ...
Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings. In the last five years, our consultants have undertaken over 700 client projects in rare diseases, constituting over 20% of our...
ON Helix 2024
ON Helix Life Science Conference 2024
Evolving business models: Pharmaceutical incubators
As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large biopharmaceutical companies were sourced externally in 2020. Sources of external ...
AI in drug discovery and development: Will it live up to the hype?
The recent explosion of generative artificial intelligence (AI) has fueled interest in and concern over the use of AI in drug discovery and research and development. ...
Where are we now? The promises and pitfalls of solid tumor CAR-T therapy
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth. While normal T-cells with effector features have difficulty infiltrating the complex tumor microenvironment, ex vivo ...
The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
The Patient Preference Survey aims to understand unmet needs related to riluzole management in people with Amyotrophic Lateral Sclerosis (ALS) and to identify which characteristics of a new formulation could better match their preferences. The survey involved 117 people with ALS (PALS) ...
Source of business for biosimilars in immunology
As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status.1 Adoption of biosimilars has continued to grow each year across therapeutic areas, and the increased competition they have generated...